SCHEMBL4417941

SCHEMBL4417941

O=c1n(C2=CCNCC2)c2ccccc2n1S(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 9/20 0.60
KDM4E B2RXH2 1/20 0.47
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 2/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
LMNA P02545 3/20 0.36
MAPK1 P28482 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
AKR1B1 P15121 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
DRD3 P35462 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PGR P06401 1/20 0.35
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4419770 0.87 HTR6 (0.60) HTR6KDM4ECYP2C9CYP2C19MAPT
SCHEMBL4420503 0.85 HTR6 (0.61) HTR6KDM4ECYP2C9CYP2C19MAPT
SCHEMBL4429587 0.84 HTR6 (0.59) HTR6KDM4ECYP2C9CYP2C19MAPT
SCHEMBL4420871 0.83 HTR6 (0.61) HTR6KDM4ECYP2C9CYP2C19MAPT
SCHEMBL4432173 0.82 HTR6 (0.59) HTR6KDM4EHTR2AHTR2CDRD3
SCHEMBL4428396 0.81 HTR6 (0.61) HTR6KDM4ECYP2C9CYP2C19MAPT
SCHEMBL4419390 0.81 HTR6 (0.57) HTR6KDM4ECYP2C9CYP2C19MAPT
SCHEMBL4419809 0.78 HTR6 (0.55) HTR6KDM4ECYP3A4HTR2AHTR2C
SCHEMBL4425213 0.75 HTR6 (0.54) HTR6KDM4ECYP2C19L3MBTL1CYP1A2
SCHEMBL4417992 0.75 HTR6 (0.56) HTR6KDM4EHTR2AHTR2CDRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US claimed
EP-1654258-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2006-05-10 EP claimed
WO-2005009996-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2005-02-03 WO claimed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US claimed
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US disclosed
EP-1654258-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2006-05-10 EP disclosed
WO-2005009996-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2005-02-03 WO disclosed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1B HTR6 1/4885KDM4E 2965/4885CYP2C9 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.